治疗炎症性肠病常见的生物制剂  

Common biological agents for the treatment of inflammatory bowel disease

作　　者：杨花花 周旭春[1] 黄怡[1] 文友飞 YANG Huahua;ZHOU Xuchun;HUANG Yi;WEN Youfei(Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China;Department of Gastroenterology,the Affiliated Hospital of Guizhou Medical University,Guizhou,Guiyang 550025,China)

机构地区：[1]重庆医科大学附属第一医院消化内科,重庆400016 [2]贵州医科大学附属医院消化内科,贵州贵阳550025

出　　处：《中国医药科学》2022年第8期68-71,共4页China Medicine And Pharmacy

摘　　要：免疫机制在炎症性肠病(IBD)的发病中起着重要作用,生物制剂针对此机制起作用,治疗IBD疗效显著。虽然可供选择的生物制剂越来越多,但众多的生物制剂如何进行选择?对英夫利昔单抗(IFX)失应答的患者下一步治疗优先选择哪种生物制剂?本文从IBD的发病机制出发,对临床上常用的生物制剂进行总结和比较,以帮助临床医生做出选择。Immune mechanisms play an important role in the pathogenes is of Inflammatory bowel disease(IBD).Biologics agents targeting the immune process are effective in the treatment of IBD.Although there are many biologics available,clinicians are often confused about how to choose from them?Which biological agent is preferred for patients who fail to respond to Infliximab(IFX)in the next treatment?In this paper,we will provide an overview of the pathogenesis,summarize and compare commonly biological agents,as well as discuss the therapeutic options of IBD.

关 键 词：炎症性肠病 发病机制 生物制剂 失应答 

分 类 号：R574[医药卫生—消化系统]